NNOX — Nano-X Imaging Ltd.

Summary of Nano-X Imaging (NNOX) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• GAAP Net Loss: $33.4 million, up from $14.1 million in Q4 2024, primarily due to a $17.5 million impairment related to restructuring.
• Revenue: $3.7 million, a 23% increase from $3.0 million in the same quarter last year, driven by teleradiology services and the acquisition of Nanox Health IT.
• Gross Loss: $3.6 million (GAAP), compared to $2.9 million in Q4 2024. Non-GAAP gross loss was $1.2 million, worsening from $0.3 million in the prior year.
• Teleradiology Revenue: $3.1 million, up from $2.8 million, with a gross profit margin of 27%.
• Cash Position: $60 million in cash and marketable securities as of December 31, 2025, up from $55.5 million at the end of Q3 2025.

2. Strategic Updates and Business Highlights

• Commercial Agreements: Entered a significant agreement with Howard Technology Solutions for deploying 300 Nanox.ARC systems over three years, with 60 expected in the first year. Additional agreements could lead to 400 systems over the next 2-3 years.
• Operational Restructuring: Transitioning manufacturing from South Korea to outsourced partners to reduce costs and improve efficiency. The Korean facility will focus on R&D.
• Market Engagement: Increased interest in Nanox products was noted at major radiology conferences (RSNA and ECR), leading to a positive shift in market perception.
• Acquisition of VasoHealthcare: Strengthened capabilities in health IT, expected to contribute to revenue from day one.

3. Forward Guidance and Outlook

• 2026 Revenue Target: Aiming for $35 million, with expectations for significant revenue growth in the second half of the year as new agreements are executed.
• Deployment Timeline: Anticipated ramp-up in system utilization and revenue generation as systems become operational and partners engage.

4. Bad News, Challenges, or Points of Concern

• Impairment Charges: The $17.5 million impairment reflects challenges in aligning manufacturing with strategic priorities, indicating potential ongoing operational inefficiencies.
• Pace of Deployment: Deployment of systems is slower than desired due to regulatory and logistical challenges, which could impact revenue timing.
• Increased Operating Expenses: Rising costs in sales and marketing, alongside general administrative expenses related to acquisitions, could pressure margins if not managed effectively.

5. Notable Q&A Insights

• U.S. Commercial Strategy: The U.S. sales team is expanding, with a focus on direct sales and partnerships to enhance market penetration.
• Korean Facility Restructuring: Minor additional restructuring costs are expected in 2026, primarily cash-based, but not significant.
• Revenue Growth Expectations: Analysts inquired about the timing of revenue growth, with management indicating a more substantial ramp-up in the latter half of 2026.
• Spending Trends: Increased spending in Q4 was attributed to seasonal factors and one-time costs, with expectations for a decline moving forward, barring participation in major conferences.

This summary encapsulates the key points discussed during the earnings call, providing a balanced view of the company's current status and future outlook.